Research Article
Clinical Evaluation of the Diagnostic Role of MicroRNA-155 in Breast Cancer
Table 4
Comparison of miR-155 expression among clinical categories.
| Pathological categories | Sample size | -fold (vs. control) | (ANOVAǂ) | (vs. control) (Tukeyᵻ) |
| Normal | 36 | | | | Histology grade | | | | | WD | 10 | | <0.001 | 0.016 | MD | 15 | | | <0.001 | PD | 11 | | | <0.001 |
| TNM stage | | | | | Stage I | 8 | | <0.001 | 0.002 | Stage II | 17 | | | <0.001 | Stage III | 11 | | | <0.001 |
| Tumor size () | | | | | T1 () | 11 | | <0.001 | 0.0015 | T2 () | 18 | | | <0.001 | T3 () | 7 | | | <0.001 |
| Lymph node involvement () | | | | | Yes | 17 | | 0.15 | <0.001 | No | 19 | | | <0.001 |
| Estrogen receptor (ER) | | | | | ER+ | 24 | | 0.84 | <0.001 | ER- | 12 | | | <0.001 |
| Progesterone receptor (PR) | | | | | PR+ | 19 | | 0.54 | <0.001 | PR- | 17 | | | <0.001 |
| HER2 | | | | | HER+ | 9 | | 0.79 | <0.001 | HER- | 27 | | | <0.001 |
| Ki-67 | | | | | ≤10% | 14 | | 0.9 | <0.001 | >10% | 22 | | | <0.001 |
|
|
WD = grade 1; MD = grade 2; PD = grade 3; ER = estrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2. ǂThe analysis of variance (ANOVA) was performed for the analysis. ᵻTukey multiple comparison.
|